Close
Find your Coloplast country website

News and press releases

  • Press release
6 Feb 2020

Coloplast delivers solid start to the year with 8% organic growth

Coloplast delivered 8% organic growth and EBIT increased by 13% to DKK 1,472m, corresponding to an EBIT margin of 31%, in the first quarter of the 2019/20 financial year. The company maintains its financial guidance for 2019/20.

Read news story

Coloplast delivered 8% organic revenue growth in the first three months of the 2019/20 financial year, while reported growth in Danish kroner was up by 9% to DKK 4,712m.

 

EBIT amounted to DKK 1,472m, a 13% increase in DKK, corresponding to an EBIT-margin of 31% against 30% last year. ROIC after tax and before special items was 47% against 44% in the same period last year.

 

-          “We continue to deliver an organic revenue growth that is twice the market growth, driven by solid growth rates across all geographical regions and business areas. I would like to highlight our strong performance in Emerging Markets driven by China, Latin America, and Russia. Also, our Wound & Skin Care business delivered a good quarter driven by the Biatain® Silicone portfolio in Europe. In other words, we are off to a good start to the year,” says Coloplast CEO Kristian Villumsen. 

 

Organic growth rates by business area were 9% in Ostomy Care, 6% in Continence Care, 9% in Interventional Urology, and 10% in Wound & Skin Care. A comprehensive price reform in France adversely affected the growth performance in the Continence Care business.

 

Looking at sales by geography, the European markets contributed with 5% growth, Other developed markets delivered 10% revenue growth, while Emerging Markets provided a 16% increase.

Coloplast continues to invest in growth
Incremental investments of up to 2% of revenue were made in the first quarter into sales and marketing initiatives across multiple markets and business areas.

 

-          “We are investing across regions with a clear focus on China, our Emerging Markets, the US, and the UK. These markets hold great potential, and our ambition is to continue to take market share, while raising the standard of care for our users,” says Kristian Villumsen.

 

Coronavirus outbreak in China

Coloplast is monitoring the Coronavirus outbreak in China closely and taking all necessary precautions to keep the company’s 2,000 employees in Zhuhai and Beijing safe. Coloplast is collaborating fully with the Chinese authorities, and the company has, in collaboration with the authorities, donated Wound Care and Ostomy Care products to the Red Cross organisation in the Hubei Province.

Financial guidance for 2019/20
Coloplast continues to expect organic revenue growth of 7-8% at constant exchange rates and a reported growth in DKK of 7-8%. Coloplast continues to expect an EBIT margin of ~31% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

The financial impact of the situation in China is uncertain. The company’s full-year guidance assumes that the situation normalises during Q2.

CONTACTS

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

+45 49 11 26 07

dklina@coloplast.com

 

Ellen Bjurgert

Vice President, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

 

 

 

Financial highlights and key ratios (DKKm)

2019/20

Q1

2018/19

Q1

Change

Revenue

4,712

4,321

9%

EBIT

1,472

1,297

13%

EBIT margin

31%

30%

 

Profit for the period

1,092

991

10%

 

Sales performance by business area

(DKKm)

2019/20

Q1

2018/19

Q1

Organic growth

Reported growth

Ostomy Care

1,907

1,736

9%

10%

Continence Care

1,686

1,579

6%

7%

Urology Care

535

479

9%

12%

Wound & Skin Care

584

527

10%

11%

Revenue

4,712

4,321

8%

9%

 

Financial guidance

 

Guidance for 2019/20

Guidance for 2019/20 (DKK)

Sales growth

7-8% (organic)

7-8%

EBIT margin

~31% (at constant exchange rates)

~31%

Capital expenditure

-

~850

Tax rate

-

~23%

 

 

 

 

  • Press release
7 Jan 2020

Coloplast awarded Enterostomal Therapy products agreement with Premier Inc.

Coloplast, a global medical device company and market leader in intimate healthcare needs, has been awarded a three-year group purchasing agreement for ostomy products with Premier Inc. in the US.

Read news story

The new agreement allows Premier members access to Coloplast’s full portfolio of ostomy products, including ostomy pouches and supporting products.

“We are delighted that Premier has added us to their Enterostomal Therapy contract. Coloplast shares Premier’s core values to improve patient outcomes and provide value to its customers, and we look forward to doing exactly that for Premier’s membership,” says Senior Vice President Manu Varma, Chronic Care North America.

The agreement is multi-source and effective for three years beginning April 1, 2020. Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and hospital systems and more than 175,000 other providers to transform healthcare.

 

About Coloplast ostomy care products

Coloplast’s range of innovative ostomy products are designed to reduce leakage and maintain healthy skin. With the SenSura® Mio portfolio and BodyFit® Technology Coloplast has taken fit, flexibility, and comfort to a new level, creating a portfolio of innovative ostomy solutions that reduce the burden of leakage and enable users to live the life they want to lead.

In addition to product solutions, Coloplast has developed Coloplast® Care, the only patient support program option with better patient outcomes. Coloplast Care provides ostomy users access to education and tools for self-assessment and individualized support from Care Advisors. Coloplast Care provides reliable information so ostomy users can better manage their care and experience a full life.

 

CONTACTS
Lina Danstrup

Senior Media Relations Manager, Corporate Communications

+45 49 11 26 07

dklina@coloplast.com

 

Ellen Bjurgert

Vice President, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com


View desktop version